S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
How major US stock indexes fared Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
How major US stock indexes fared Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
How major US stock indexes fared Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
How major US stock indexes fared Thursday, 3/28/2024
NASDAQ:ORMP

Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis

$2.92
+0.10 (+3.55%)
(As of 03/28/2024 ET)
Today's Range
$2.78
$3.14
50-Day Range
$2.21
$3.58
52-Week Range
$1.67
$5.25
Volume
211,195 shs
Average Volume
139,526 shs
Market Capitalization
$118.32 million
P/E Ratio
20.86
Dividend Yield
N/A
Price Target
N/A
ORMP stock logo

About Oramed Pharmaceuticals Stock (NASDAQ:ORMP)

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

ORMP Stock Price History

ORMP Stock News Headlines

ORMP Apr 2024 2.500 put
Make This $3 Trade the Instant the Opening Bell Rings
Since the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…
Oramed Pharmaceuticals Inc.: Oramed Letter to Shareholders
Oramed Letter to Shareholders
Make This $3 Trade the Instant the Opening Bell Rings
Since the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…
Oramed Pharmaceuticals, Inc.
ORMP: Advancing Development Efforts in China
8-K: ORAMED PHARMACEUTICALS INC.
See More Headlines
Receive ORMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2024
Today
3/29/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ORMP
Employees
12
Year Founded
N/A

Profitability

Net Income
$5.53 million
Net Margins
-747.02%
Pretax Margin
379.70%

Debt

Sales & Book Value

Annual Sales
$1.34 million
Book Value
$4.04 per share

Miscellaneous

Free Float
35,657,000
Market Cap
$118.32 million
Optionable
Optionable
Beta
1.83
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

ORMP Stock Analysis - Frequently Asked Questions

How have ORMP shares performed in 2024?

Oramed Pharmaceuticals' stock was trading at $2.31 at the start of the year. Since then, ORMP shares have increased by 26.4% and is now trading at $2.92.
View the best growth stocks for 2024 here
.

When is Oramed Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ORMP earnings forecast
.

How were Oramed Pharmaceuticals' earnings last quarter?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) posted its quarterly earnings data on Wednesday, March, 6th. The biotechnology company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.04. Oramed Pharmaceuticals had a negative net margin of 747.02% and a negative trailing twelve-month return on equity of 7.15%.

What other stocks do shareholders of Oramed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include Compugen (CGEN), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), DURECT (DRRX), OPKO Health (OPK), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN).

Who are Oramed Pharmaceuticals' major shareholders?

Oramed Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BML Capital Management LLC (3.13%), Murchinson Ltd. (2.60%), Barclays PLC (0.03%), Citadel Advisors LLC (0.00%), Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Kevin Rakin, Michael Rabinowitz, Nadav Kidron and Yadin Rozov.
View institutional ownership trends
.

How do I buy shares of Oramed Pharmaceuticals?

Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ORMP) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners